SY

Sygnis Pharma AG

  • CIK: 0001106774
  • EIN: 00-0000000
  • Business address: IM NEUENHEIMER FELD 515, HEIDELBERG, Germany, 69120

Information

  • Mailing address
    IM NEUENHEIMER FELD 515, HEIDELBERG, 2M, 69120
  • Phone
    49 6221 454 812
  • State location
    Germany
  • State of incorporation
    N/A
  • Fiscal year end
    N/A
  • SIC
    8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
  • Filings
    N/A

About Sygnis Pharma AG

Sygnis Pharma AG (CIK: 0001106774) is an American company incorporated in the state of Germany. Head office is located at IM NEUENHEIMER FELD 515, HEIDELBERG, Germany, 69120. Work in the industry 8731 - (CF Office: Office of Trade & Services) SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH. Sygnis Pharma AG is a public company and trade via Over-The-Counter (OTC).

Old names:

  • LION BIOSCIENCE AG from 2000-16-Feb to 2005-19-May

Ownership

Updating!

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Sygnis Pharma AG

Filings Format Description Filed/Effective File/Film Number
F-X Document

For appointment of agent for service of process by issuers registering securities

Acc-no: 0000897069-08-001601 (33 Act) Size: KB		 Oct-21-2008

000-30850

081132816
CB Document

Notification form filed in connection with certain tender offers, business combinations and rights offerings, in which the subject company is a foreign private issuer of which less than 10% of its securities are held by U.S. persons

Acc-no: 0000897069-08-001599 (34 Act) Size: KB		 Oct-21-2008

005-77995

081132810
15-12G Document

Notice of termination of registration of a class of securities under Section 12(g)

Acc-no: 0001193125-05-111151 (34 Act) Size: KB		 May-19-2005

000-30850

05843413
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-05-053535 (34 Act) Size: KB		 Mar-17-2005

000-30850

05687466
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-05-036584 (34 Act) Size: KB		 Feb-25-2005

000-30850

05638846
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-05-028364 (34 Act) Size: KB		 Feb-14-2005

000-30850

05604415
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-05-018180 (34 Act) Size: KB		 Feb-03-2005

000-30850

05571714
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-199736 (34 Act) Size: KB		 Nov-18-2004

000-30850

041154033
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-199709 (34 Act) Size: KB		 Nov-18-2004

000-30850

041153992
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-196664 (34 Act) Size: KB		 Nov-15-2004

000-30850

041142555
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-187127 (34 Act) Size: KB		 Nov-05-2004

000-30850

041121165
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-172060 (34 Act) Size: KB		 Oct-15-2004

000-30850

041080174
20-F Document

Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d)

Acc-no: 0001193125-04-164383 ( Act) Size: KB		 Sep-30-2004

000-30850

041054091
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-133746 ( Act) Size: KB		 Aug-06-2004

000-30850

04956474
20-F/A Document

Amendment to Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d)

Acc-no: 0001193125-04-065161 ( Act) Size: KB		 Apr-20-2004

000-30850

04742000
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-054705 ( Act) Size: KB		 Mar-31-2004

000-30850

04704872
POS AM Document

Post-effective amendment to a registration statement that is not immediately effective upon filing

Acc-no: 0001193125-04-048180 ( Act) Size: KB		 Mar-24-2004

333-90730

04687098
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-033772 ( Act) Size: KB		 Mar-03-2004

000-30850

04646006
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-04-015902 ( Act) Size: KB		 Feb-06-2004

000-30850

04571643
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001193125-03-096152 ( Act) Size: KB		 Dec-18-2003

000-30850

031061186

Recent 20 filings. View all Sygnis Pharma AG filings

Reviews

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Frequently Asked Questions

Tags:

  • Sygnis Pharma AG overview
  • Sygnis Pharma AG job
  • Sygnis Pharma AG stock
  • Sygnis Pharma AG ownership
  • Sygnis Pharma AG CEO
  • Sygnis Pharma AG documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

Zymergen Inc.
Update: Aug 26, 2022
XXSYS TECHNOLOGIES INC /CA
Update: Aug 25, 2022
WHISTLER INC
Update: Aug 25, 2022
WCG Clinical, Inc.
Update: Aug 25, 2022
Viventia Biotech Inc.
Update: Aug 24, 2022
VIACELL INC
Update: Aug 24, 2022

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 3785 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 2570 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 4187 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 3283 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 2816 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 1488 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 1447 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 1408 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 4188 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by